1.	A Pilot Study of EM-1421 for the Treatment of Cervical Intraepithelial Neoplasia Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EM-1421 #201, NCT00154089
2.	Tetra-O-Methyl Nordihydroguaiaretic Acid in Treating Patients With Recurrent High-Grade Glioma Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Completed Age: 18 and over Sponsor: NCI, Other Protocol IDs: NABTT-0503 CDR0000515952, U01CA062475, NABTT-0503, NCT00404248
3.	Study of Intralesional Injection of M4N in Patients With Refractory Malignant Tumors of the Head and Neck Phase: Phase I Type: Treatment Status: Completed Age: 18 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: M4N001, NCT00057512
4.	Dose Escalation Study of EM-1421 for the Treatment of Recurrent or Refractory Solid Tumors Phase: Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EM-1421 #101, NCT00259818
5.	A Phase 1 Continuous Intravenous Infusion Study of Terameprocol (EM-1421) in Subjects With Refractory Solid Tumors Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EM-1421 #104, NCT00664586
6.	Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: EM-1421 #105, NCT00664677